Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog
RSS FEED
FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Remorseful Regulator Leads Reform Fight
- Lightning Round: AT&T, Verizon, Novartis and More
- Lightning Round OT: Alcoa, Weight Watchers and More
- Why Amazon Rules Retail
- Nordic American: Sinking Ship or Titan Tanker?
- Cramer: What Monday’s Housing Number Really Means
- Cramer: Buy These Banks, If...
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Web Editor, Mad Money
Allos Therapeutics “could be an opportunity,” Cramer said Thursday, for investors looking to speculate on the fight against cancer.
The company plans to trade launch Folotyn, a drug for refractory peripheral T-cell lymphoma, to physicians at the American Society of Hematology on Dec. 5, Cramer said, and the meeting could be “a big catalyst” for the stock.
Not to mention, Allos [ALTH
Loading...
()
] is developing Folotyn for multiple indications, “the jackpot when it comes to cancer research,” including CTCL, a rare form of non-Hodgkins lymphoma and lung cancer. Additional data on the trials is due out later this year and in the first half of 2010.
Folotyn is so potentially big that it makes Allos appear to be “a very cheap stock,” Cramer said. Sales of the drug could reach $300 million in the US, but even if the final tally’s only $150 million, that still adds up to about $5 a share for the stock. And ALTH closed Thursday at $5.89.
The stock took a hit as a result of Allos’ Oct. 7 secondary offering, Cramer said, and “it’s been all downhill since then.” But the company held $84 million in cash at the end of the quarter, so another raising of cash is most likely out of the question. More importantly, though, investors now have the chance to buy ALTH almost 25% lower than its trading price before Folotyn was approved on Sept. 24.
Once the drug hits the commercial market in January, Cramer said, Allos’ stock “should go higher.” But he wanted to hear from CEO Paul Berns before making the call. Watch the video for the full interview.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes